Dendritic Cell Immunotherapy for Malignant Gliomas

摘要: The prognosis for patients with malignant gliomas remains poor despite advances in surgical technique, chemotherapy and radiation therapy. Median survival glioblastoma multiforme, the most aggressive deadliest form of brain cancer, only fifteen months even after optimal treatment resection followed by chemoradiation grim can be attributed to infiltrative nature disease, a central nervous system microenvironment that escape immune surveillance resistance tumor chemotherapy. In recent trials, dendritic cells have demonstrated an ability promote effective anti-tumor response sensitize glioma This review will discuss results dendritic-cell based immunotherapy clinical trials explore future strategies DC vaccines immunotherapy.